$COSM Due Diligence: Analyzing the Buyback, Financials, Risks, and Upcoming Catalysts
# Research Update – July 13th, 2026
**Summary (TL;DR)**
**Research Update:** Since my original DD, I’ve continued reviewing SEC filings and company announcements. The buyback has increased to **4.355 million shares repurchased** (approximately **$901,000**, or **18.02%** of the $5 million authorization). I also verified that recent increases in CEO Greg Siokas’ ownership came primarily through **debt-for-equity exchanges**, not recent open-market purchases, and that **4.87 million Series B warrants expired unexercised**, reducing potential future dilution. I’ve also updated my methodology to rely on the **latest SEC filings** whenever they differ from third-party websites like Finviz. As new filings are released, I’ll continue updating this research so it’s based on the most current verified information available.
# Buyback Continues to Progress
Since my original DD, CEO Greg Siokas posted another update indicating that Cosmos Health has continued repurchasing shares in the open market.
According to the update:
* **Total shares repurchased:** **4,355,000**
* **Total capital deployed:** **Approximately $901,000**
* **Additional shares since the previous update:** **215,000**
* **Additional capital deployed:** **Approximately $70,000**
Based on the company’s **$5 million** authorization:
* **Authorization completed:** **18.02%**
* **Authorization remaining:** **81.98%**
* **Remaining authorization:** **Approximately $4.099 million**
The cumulative average repurchase price is now approximately **$0.2069 per share**.
The continued repurchases suggest the company is still actively executing the authorization rather than treating it as a one-time announcement.
One statement from the CEO that I think is worth noting is:
“Our continued repurchases reflect a firm conviction that Cosmos Health shares remain undervalued.”
That’s management’s opinion and should be viewed as such. Investors should form their own conclusions based on the company’s financial results, capital structure, and future execution rather than management commentary alone.
**Current status:** This information comes from the CEO’s public X account. I plan to update this section again once the company publishes its customary press release or SEC filing confirming the latest buyback totals.
# I would also update the buyback timeline
|**Date**|**Shares Repurchased**|**Approx. Dollars Deployed**|
|:-|:-|:-|
|July 1|2.65M|\~$500K|
|July 2|3.42M|\~$650K|
|July 6|3.64M|\~$700K|
|July 7|3.87M|\~$758K|
|July 8|4.06M|\~$811K|
|July 9|4.14M|\~$831K|
|**Latest Update**|**4.355M**|**\~$901K**\*|
\* Based on the CEO’s public update. Awaiting formal company confirmation.
https://preview.redd.it/v2jb7ndiv1dh1.png?width=602&format=png&auto=webp&s=36e633f24dc327f2fc99a5aa42c16078e4d604d8
One more thing I noticed: the increase from **4.14M to 4.355M** is **215,000 shares**, which is very close to the incremental purchases we’ve been seeing over the past several updates (roughly 190,000–230,000 shares each). That consistency may be worth mentioning as an observation, but I’d avoid implying it predicts the pace of future repurchases because the company can change its buying activity at any time.
# Original Reddit, July 11th, 2026
**Before I begin:** I originally shared a few separate posts covering different aspects of COSM, including the buyback, valuation math, and recent news. I wasn’t aware that making multiple posts on the same ticker could trigger Reddit’s filters, so those posts were removed. Rather than reposting them individually, I decided to combine everything into one comprehensive due diligence post that follows the subreddit’s guidelines. My goal isn’t to promote the stock. It’s to present the facts, my analysis, the risks, and the potential catalysts in one place, and hopefully get constructive feedback from the community.
**Summary (TL;DR)**
I’ve spent the last several days reading Cosmos Health’s press releases, financial statements, and buyback announcements because I wanted to understand whether the recent developments materially change the investment thesis.
This is **not financial advice**, and I’m **not recommending anyone buy or sell COSM**. I currently own shares, so I have a bias, and I’m posting this because I’d genuinely like others to challenge my analysis and point out anything I may have missed.
# 1. Company Overview
Cosmos Health (NASDAQ: COSM) is a diversified healthcare company operating in several business segments, including:
• Pharmaceutical distribution
• Proprietary nutraceutical brands (Sky Premium Life)
• Medical devices
• Contract manufacturing
Management has stated that one of its long-term objectives is shifting revenue toward proprietary products because they generally carry significantly higher margins than pharmaceutical distribution.
# 2. Financial Overview
Recent developments have caught my attention.
# Preliminary Q2 2026 Revenue
Approximately **$19.4 million**
# Preliminary H1 2026 Revenue
Approximately **$37.3 million**
# Year-over-Year Growth
Approximately **31%**
If confirmed during Q2 earnings, this would represent another record revenue period for the company.
Revenue alone isn’t enough.
The important question is whether management can convert that growth into stronger margins and eventually consistent profitability.
# 3. Why Is the Market Skeptical?
Before discussing the bullish thesis, I think it’s important to understand why many investors remain bearish.
Some of the concerns I see repeatedly include:
* Significant historical dilution
* Multiple reverse splits
* Low historical gross margins
* Inconsistent profitability
* Concerns surrounding the digital treasury strategy
* Small-cap healthcare execution risk
I think these concerns are legitimate.
One comment that stood out to me was:
“They’re just buying back a small percentage of the dilution from the past five years.”
That’s objectively a fair criticism.
The key question isn’t whether dilution happened.
It clearly did.
The question is whether management’s capital allocation strategy has changed going forward.
# 4. The Buyback
This is what originally caught my attention.
The board authorized a **$5 million** share repurchase program.
Since then:
|**Date**|**Total Shares Repurchased**|
|:-|:-|
|July 1|2.65M|
|July 2|3.42M|
|July 6|3.64M|
|July 7|3.87M|
|July 8|4.06M|
|July 9|4.14M|
Current status:
• Shares repurchased: **4.14 million**
• Cash deployed: **\~$829,000**
• Authorization completed: **16.58%**
• Authorization remaining: **83.42%**
The interesting part isn’t today’s purchase.
It’s the consistency.
Rather than announcing one buyback and stopping, management has continued updating investors almost every trading day.
**Estimated Buyback Completion**
Based on the company’s announcements, Cosmos Health has deployed approximately **$829,000** over the first **6 trading days** of the program, averaging roughly **$138,000 per trading day**.
At that pace, the remaining **$4.17 million** authorization would take approximately **30 additional trading days** to complete.
Assuming management continues repurchasing shares at a similar rate, and accounting only for normal market trading days (excluding weekends and market holidays), the buyback could be substantially completed around **late August to early September 2026**.
This is **not a prediction**. The actual timeline could be shorter or longer depending on trading volume, share price, corporate blackout periods, management’s capital allocation decisions, and whether the company chooses to complete the full authorization.
If completed, the buyback would represent one of the most significant capital allocation events for the company in recent years. Whether it ultimately creates shareholder value will depend not only on reducing the share count but also on management’s ability to continue growing revenue, improve margins, and move the business toward sustainable profitability.
# 5. Buyback Math
I wanted to understand how much the reduced share count could matter.
Current figures:
Market Cap
Approximately **$16 million**
Outstanding Shares
Approximately **49.8 million**
If today’s repurchased shares have been retired, the effective share count falls to roughly **45.6 million shares**.
Assuming the market capitalization remained unchanged, that would mathematically imply a share price around **$0.32**.
Again:
**This is not a price target.**
It’s simply the mathematical effect of fewer shares representing the same total company value.
If the entire $5 million authorization were completed near the current average purchase price, the share count could decline substantially further.
The actual outcome will depend on the average repurchase price and whether management completes the full authorization.
# 6. Additional Business Developments
One announcement that didn’t receive much attention was the Qatar distribution agreement.
The company secured an initial purchase order for **31,000 Sky Premium Life units** through the owner of Qatar’s largest pharmacy chain.
The company did not disclose the dollar value.
Based on wholesale pricing for similar products, I estimate the initial order could reasonably be worth somewhere between:
Approximately **$300,000** and Approximately **$1 million**
The exact number isn’t the important part.
What interests me is the possibility of recurring orders if the rollout proves successful.
Management has also publicly stated a long-term objective of increasing gross margins from approximately **12% today** to approximately **35% by 2029** through expansion of higher-margin proprietary products.
# 7. Upcoming Catalysts
# July 15
Annual General Meeting
Potential updates regarding:
* Buyback progress
* Business strategy
* Nasdaq compliance
# Mid-August
Expected Q2 earnings
This is probably the most important catalyst because investors will be looking for:
* Confirmation of preliminary revenue
* Margin improvement
* Cash flow
* Profitability trends
# 8. Risks
This is where I’d appreciate additional feedback.
Things that could invalidate my thesis include:
* Future dilution
* Buyback slowing or stopping
* Revenue growth slowing
* Margins failing to improve
* Weak Q2 earnings
* Continued operating losses
* General weakness in small-cap healthcare stocks
* don’t think any of these risks should be ignored.
# 9. Bull vs Bear
# Bull Case
Revenue continues growing.
Margins gradually improve.
Management completes most or all of the buyback.
Investor confidence improves.
The market begins assigning a higher valuation.
# Bear Case
Revenue growth slows.
Margins remain weak.
The company returns to issuing shares.
The buyback doesn’t materially change shareholder value.
The market continues assigning a discounted valuation.
# 10. My Conclusion
I’m not posting this because I believe COSM is guaranteed to outperform.
I’m posting it because I think the company looks materially different today than it did several months ago.
Historical dilution, reverse splits, and profitability concerns are all real.
At the same time, recent revenue growth, the active buyback, expansion into higher-margin proprietary products, and several near-term catalysts are enough for me to continue following the company closely.
I’d genuinely appreciate feedback from both bulls and bears.
If I’ve overlooked something, I’d rather know now than after making an investment decision.
**Not financial advice. Please do your own due diligence before investing.**